Study Description
This study is an open-label, multicenter, single-arm, observational post-marketing
surveillance. The investigators will collect safety information and evaluate effectiveness in patients
who are prescribed Beovu ® Injection, Beovu ®Prefilled Syringe (brolucizumab) in the
approved indication after receiving informed consent over a period of 12 weeks. In
addition, longer-term data (24 weeks, optionally 36 weeks) will be collected.
Interventions
brolucizumab
Eligibility Criteria
Inclusion Criteria:
1. Patients aged ≥18 years with nAMD that are prescribed with Brolucizumab as per
approved local product information
2. Patients who consent to participate in the study after the purpose and nature of the
study have clearly explained to them (written informed consent)
Exclusion Criteria:
1. Contraindications as per local prescribing information 1) Hypersensitivity to the
active substance or to any of the excipients. 2) Active or suspected ocular or
periocular infection. 3) Active intraocular inflammation.
2. Patients participating in other investigational drug trial
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.